Los Angeles Capital Management
FULC icon

Los Angeles Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Los Angeles Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.26K Sell
295
-620
-68% -$5.75K ﹤0.01% 2270
2025
Q4 		$7.87K Buy
+915
New +$9.31K ﹤0.01% 2160
2025
Q3 		– Sell
-13,465
Closed -$92.6K – 1423
2025
Q2 		$92.6K Buy
+13,465
New +$72K ﹤0.01% 1257
2024
Q3 		– Sell
-21,038
Closed -$130K – 1213
2024
Q2 		$130K Buy
+21,038
New +$159K ﹤0.01% 1149
2021
Q1 		– Sell
-20,757
Closed -$243K – 1605
2020
Q4 		$243K Sell
20,757
-10,713
-34% -$121K ﹤0.01% 1437
2020
Q3 		$250K Buy
31,470
+15,891
+102% +$191K ﹤0.01% 1327
2020
Q2 		$285K Buy
15,579
+4,950
+47% +$77.9K ﹤0.01% 1298
2020
Q1 		$127K Buy
+10,629
New +$170K ﹤0.01% 1269

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Los Angeles Capital Management's FULC Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Fulcrum Therapeutics (FULC) stake by 68% in Q1 2026, selling an estimated $5.75K and leaving 295 shares worth $2.26K. The position accounts for ﹤0.01% of the portfolio, ranked #2270.

Los Angeles Capital Management first reported a position in FULC in Q1 2020 and has held it in 8 quarters since. The position peaked at $285K in Q2 2020. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Los Angeles Capital Management held 295 shares of Fulcrum Therapeutics worth $2.26K as of Q1 2026.
  • Los Angeles Capital Management sold 620 Fulcrum Therapeutics shares in Q1 2026, an estimated $5.75K.
  • Fulcrum Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2270 holding.
  • Los Angeles Capital Management first reported a position in Fulcrum Therapeutics in Q1 2020 and has held it in 8 quarters since.
  • Los Angeles Capital Management's Fulcrum Therapeutics position peaked at $285K in Q2 2020.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.